With 0.58 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.61 million shares. The 52-week range on HBIO shows that it touched its highest point at $3.60 and its lowest point at $0.29 during that stretch. It currently has a 1-year price target of $3.00. Beta for the stock currently stands at 1.44.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of HBIO was up-trending over the past week, with a rise of 16.38%, but this was down by -10.25% over a month. Three-month performance dropped to -73.35% while six-month performance fell -85.53%. The stock lost -89.54% in the past year, while it has lost -83.20% so far this year. A look at the trailing 12-month EPS for HBIO yields -1.32 with Next year EPS estimates of 0.06. For the next quarter, that number is -0.03. This implies an EPS growth rate of 16.67% for this year and 71.43% for next year.
Float and Shares Shorts:
At present, 44.21 million HBIO shares are outstanding with a float of 37.29 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for HBIO since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of $0.04521246 being high and $0.04478754 being low. For HBIO, this leads to a yearly average estimate of $0.045.
